Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation: Initial european experience

Park, Jai‐Wun; Bethencourt, Armando; Sievert, Horst; Santoro, Gennaro; Meier, Bernhard; Walsh, Kevin; Lopez‐Minquez, Jose Ramon; Meerkin, David; Valdés, Mariano; Ormerod, Oliver; Leithäuser, Boris

doi:10.1002/ccd.22764

Cited by 365 publications

(78 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This setup facilitates loading into the delivery sheath and is intended to minimize air embolism. The device is delivered to the LAA through a TorqVue 45° × 45° double-bend sheath (sizes: 16-25 mm: 12 or 14 French with adapter, sizes 25-34 mm: 14 French) [12].…”

Section: Amplatzer Amuletmentioning

confidence: 99%

Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Amplatzer Amuletmentioning

confidence: 99%

Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a multi-center and a single center study, in total five device embolisations are reported in three and two patients respectively (3,4). Worldwide, 700 cases have been performed with the AMPLATZER device, and 6 cases of device embolisation are verbally confirmed from the AGA Medical Corporation.…”

Section: Resultsmentioning

confidence: 99%

Left Atrial Appendage (LAA) Closure – device disengagement as a serious complication and how it can be easily removed

Burgazli¹,

Erdoğan²,

Chasan³

et al. 2012

Balkan Med J

View full text Add to dashboard Cite

A stroke attack in the brainstem area as a serious complication of atrial fibrillation (AF) in a 51 year old woman with known paroxysmal AF (CHADS² score 3) was treated with LAA occlusion procedure after the complication of arterial bleeding secondary to anticoagulation therapy. LAA closure device embolisation was developed following the LAA occlusion procedure. The device was located and removed successfully from the systemic circulation.

show abstract

“…The Amplatzer Cardiac Plug (ACP) is a self-expandable device which has demonstrated favorable results. [46][47][48][49][50] The largest series is the European multicenter experience obtained from 22 centers and included 1047 consecutive patients being treated with the ACP device between December 2008 and November 2013. 49 All patients were included in this dedicated database without roll-in subjects, though it should be acknowledged that the majority of operators did have prior experience with device implantation.…”

Section: Procedural Setting and Operator Experiencementioning

confidence: 99%

Left Atrial Appendage and Closure

Holmes

Reddy

2016

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Abstract-Patients with nonvalvular atrial fibrillation have a 4-to 5-fold increase in strokes and that rhythm may be responsible for 15% to 20% of all strokes, particularly in the elderly. In this setting, thrombus in the left atrial appendage has been found to be the source of stroke in 90% of cases. Although oral anticoagulants have been found effective in reducing stroke rates, for a variety of issues, they may only be used in 40% to 50% of patients at increased risk for stroke. Given pathophysiology of stroke, site-specific therapy directed at left atrial appendage occlusion has been now studied for stroke prevention, and one device is FDA approved (Watchman). A meta-analysis of 2 randomized clinical trials and 2 registries with this device documented the following: (1) patients receiving the device had significantly fewer hemorrhagic strokes (hazard ratio 0.22, P=0.004); (2) a significant reduction in cardiovascular or unexplained death (hazard ratio 0.48, P=0.004); (3) more ischemic strokes in the device group; however, when periprocedural events were excluded, the difference was not significant; and (4) a significant reduction in nonprocedural bleeding with the device (hazard ratio 0.51, P=0.006) versus control. At present, the only device approved in the United States is indicated in patients with nonvalvular atrial fibrillation with acceptable anatomy who are at increased risk for stroke and would be candidates for anticoagulation in whom there is concern about the risk/benefit ratio for chronic anticoagulation. Unresolved issues include optimal patient selection criteria, the role of devices in patients in whom anticoagulation is contraindicated, and the relative role of novel oral anticoagulants versus the device which has not been tested in randomized trials. (Circ Cardiovasc Interv. 2016;9:e002942.

show abstract

Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation: Initial european experience

Abstract: The implantation of the ACP device is a feasible method for percutaneous occlusion of the LAA.

Cited by 365 publications

References 47 publications

Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet

Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet

Left Atrial Appendage (LAA) Closure – device disengagement as a serious complication and how it can be easily removed

Left Atrial Appendage and Closure

Contact Info

Product

Resources

About